Related Experiment Video
Updated: Jun 16, 2026
10:52
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Where next for BTKi-BCL2i combinations in mantle cell lymphoma?
1Churchill Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
British Journal of Haematology
|June 14, 2026
Summary
Ibrutinib plus venetoclax showed promising efficacy in patients with relapsed/refractory mantle cell lymphoma. This combination therapy offers a new treatment option for this challenging hematologic malignancy.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma.
- Relapsed/refractory MCL has limited treatment options and poor prognosis.
- Novel therapeutic strategies are needed for MCL patients.
Purpose of the Study:
- To evaluate the efficacy and safety of ibrutinib plus venetoclax in patients with relapsed/refractory MCL.
- To present the final analysis of the phase 3 SYMPATICO study.
Main Methods:
- Phase 3, randomized, controlled trial (SYMPATICO study).
- Patients with relapsed/refractory MCL received ibrutinib plus venetoclax or physician's choice of therapy.
- Primary endpoint was progression-free survival.
Main Results:
- Ibrutinib plus venetoclax demonstrated a significant improvement in progression-free survival compared to the control arm.
- Objective response rates were higher in the combination arm.
- Adverse events were manageable and consistent with known profiles.
Conclusions:
- Ibrutinib plus venetoclax is an effective and tolerable treatment for relapsed/refractory MCL.
- This combination represents a potential new standard of care for this patient population.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...